These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 21079513)

  • 1. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.
    Andersen ES; Moessner BK; Christensen PB; Kjær M; Krarup H; Lillevang S; Weis N
    Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):41-4. PubMed ID: 21079513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
    D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
    J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
    Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
    Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C.
    Stasi C; Arena U; Zignego AL; Corti G; Monti M; Triboli E; Pellegrini E; Renzo S; Leoncini L; Marra F; Laffi G; Milani S; Pinzani M
    Dig Liver Dis; 2013 Oct; 45(10):840-3. PubMed ID: 23660078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
    World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response.
    Lee HW; Chon YE; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Jung KS; Park YN; Han KH
    Gut Liver; 2016 May; 10(3):429-36. PubMed ID: 26347515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
    Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
    Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
    Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
    Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
    Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
    World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
    ANRS CO13 HEPAVIH Cohort
    AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver stiffness diminishes with antiviral response in chronic hepatitis C.
    Hézode C; Castéra L; Roudot-Thoraval F; Bouvier-Alias M; Rosa I; Roulot D; Leroy V; Mallat A; Pawlotsky JM
    Aliment Pharmacol Ther; 2011 Sep; 34(6):656-63. PubMed ID: 21752038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C.
    Forestier N; Gaus A; Herrmann E; Sarrazin C; Bojunga J; Poynard T; Albert J; Gerber L; Schneider MD; Dultz G; Zeuzem S; Friedrich-Rust M
    J Gastrointestin Liver Dis; 2012 Dec; 21(4):367-73. PubMed ID: 23256119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.
    Ueda Y; Marusawa H; Kaido T; Ogura Y; Oike F; Mori A; Ogawa K; Yoshizawa A; Hatano E; Miyagawa-Hayashino A; Haga H; Egawa H; Takada Y; Uemoto S; Chiba T
    J Viral Hepat; 2012 Jan; 19(1):32-8. PubMed ID: 21129128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy.
    Koh C; Heller T; Haynes-Williams V; Hara K; Zhao X; Feld JJ; Kleiner DE; Rotman Y; Ghany MG; Liang TJ; Hoofnagle JH
    Aliment Pharmacol Ther; 2013 May; 37(9):887-94. PubMed ID: 23461575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
    Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
    J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.